Relmada Therapeutics, Inc. (RLMD) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 5 Buy, 2 Hold, 1 Sell.
The consensus price target is $9.00 (low: $8.00, high: $10.00), representing an upside of 25.2% from the current price $7.19.
Analysts estimate Earnings Per Share (EPS) of $-2.70 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.65 vs est $-2.70 (beat +2%). 2025: actual $-1.45 vs est $-1.05 (missed -38.4%). Analyst accuracy: 85%.
RLMD Stock — 12-Month Price Forecast
$9.00
▲ +25.17% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Relmada Therapeutics, Inc., the average price target is $9.00, with a high forecast of $10.00, and a low forecast of $8.00.
The average price target represents a +25.17% change from the last price of $7.19.
Highest Price Target
$10.00
Average Price Target
$9.00
Lowest Price Target
$8.00
RLMD Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Relmada Therapeutics, Inc. in the past 3 months
EPS Estimates — RLMD
85%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.65
vs Est –$2.70
▲ 2.0% off
2025
Actual –$1.45
vs Est –$1.05
▼ 27.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RLMD
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
